Question-and-Answer Session
Operator
(Operator Instructions). Your first question comes from Katherine Kim – Banc of America Securities.
Katherine Kim – Banc of America Securities
The first is the ASH abstracts which should be available soon. Do you expect to have any incremental or information in those abstracts from the presentations you’re expecting? Or is this just going to be pretty much placeholders?
Paul Berns
I’ll have Pablo speak to that because I think as you know, ASH is a organization like many tier one medical type conferences where the information is embargoed up until the point of which they really buy the organization at the meeting. But to that I’ll have Pablo comment.
Pablo Cagnoni
It’s our understanding that the abstract will be posted online at the ASH website on November 10. I’m afraid because, as Paul mentioned, because of the nature of the embargo placed by ASH on the data we cannot comment on what’s contained in those abstracts.
Katherine Kim – Banc of America Securities
But if they’re going to, can you just say if there’s going to be any incremental information? Not necessarily talk about the data, but just if there’s going to be new things? Or is it going to be just – like, for example, the PROPEL trial, is it just going to be a placeholder showing this interim data that was – the top line data that was announced back in May.
Pablo Cagnoni
There is more data in the abstract than was presented to the press release in May. That’s all I can say at this point.
Katherine Kim – Banc of America Securities
OK. And then, for PROPEL, beyond the response rates and the duration of response, what other parameters should we be focused on?
Pablo Cagnoni
Well, those are the two key end points of efficacy as you mentioned, so the primary endpoint of the study as you know is overall response rate and I think you should focus on the response rate. You should focus on the number of complete responses in this study and the durability of those responses. All that in the context of the safety of PROPEL compound considering the population that was treated in the study which as we mentioned several times, was a very heavily pre-treated group of patients with PTCL.
All this has to be put into context of that group of patients. They’re heavily pre-treated, therefore, the safety of PROPEL as well has to be put in context and the efficacy has to be put in that context as well. But I think you hit of the two key efficacy endpoints. I will just add that safety is the other key part of that.
- To read the full transcript on Seeking Alpha, click here »
